These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21575312)

  • 1. 'Universal' access for MDR-TB limited without the involvement of the private sector.
    Pinto L; Udwadia Z
    Int J Tuberc Lung Dis; 2011 Jun; 15(6):851; author reply 851-2. PubMed ID: 21575312
    [No Abstract]   [Full Text] [Related]  

  • 2. Time to put boots on the ground: making universal access to MDR-TB treatment a reality.
    Keshavjee S; Farmer PE
    Int J Tuberc Lung Dis; 2010 Oct; 14(10):1222-5. PubMed ID: 20843411
    [No Abstract]   [Full Text] [Related]  

  • 3. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidrug resistant tuberculosis: trends and control.
    Prasad R; Gupta N; Singh M
    Indian J Chest Dis Allied Sci; 2014; 56(4):237-46. PubMed ID: 25962197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited access to drugs for resistant tuberculosis: a call to action.
    Bélard S; Janssen S; Osbak KK; Adegnika AA; Ondounda M; Grobusch MP
    J Public Health (Oxf); 2015 Dec; 37(4):691-3. PubMed ID: 25527468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.
    Sloan DJ; Lewis JM
    Trans R Soc Trop Med Hyg; 2016 Mar; 110(3):163-72. PubMed ID: 26884496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistant tuberculosis: what is to be done?
    Schluger NW
    Chest; 2009 Aug; 136(2):333-335. PubMed ID: 19666753
    [No Abstract]   [Full Text] [Related]  

  • 8. Ethical issues in tuberculosis diagnosis and treatment.
    Selgelid MJ; Reichman LB
    Int J Tuberc Lung Dis; 2011 Jun; 15 Suppl 2():9-13. PubMed ID: 21740653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a standardised multidrug-resistant/extensively drug-resistant tuberculosis assessment and monitoring tool.
    Migliori GB; Sotgiu G; Jaramillo E; Mirzayev F; Centis R; Colvin C; Richardson MD
    Int J Tuberc Lung Dis; 2009 Oct; 13(10):1305-8. PubMed ID: 19793438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrated MDR-TB management programme results in favourable outcomes in northern Taiwan.
    Yu MC; Chen HY; Chien SH; Jou R
    Eur Respir J; 2015 Jan; 45(1):272-5. PubMed ID: 25102959
    [No Abstract]   [Full Text] [Related]  

  • 11. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
    Coker R
    Int J Tuberc Lung Dis; 2002 Aug; 6(8):649-50. PubMed ID: 12150473
    [No Abstract]   [Full Text] [Related]  

  • 12. Picking up the pace--scale-up of MDR tuberculosis treatment programs.
    Keshavjee S; Farmer PE
    N Engl J Med; 2010 Nov; 363(19):1781-4. PubMed ID: 21047219
    [No Abstract]   [Full Text] [Related]  

  • 13. Increasing transparency in partnerships for health--introducing the Green Light Committee.
    Gupta R; Cegielski JP; Espinal MA; Henkens M; Kim JY; Lambregts-Van Weezenbeek CS; Lee JW; Raviglione MC; Suarez PG; Varaine F
    Trop Med Int Health; 2002 Nov; 7(11):970-6. PubMed ID: 12390604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues facing TB control (7). Multiple drug-resistant tuberculosis.
    Raviglione MC
    Scott Med J; 2000 Oct; 45(5 Suppl):52-5; discussion 56. PubMed ID: 11130318
    [No Abstract]   [Full Text] [Related]  

  • 15. [Multidrug-resistant tuberculosis: challenges of a global emergence].
    Comolet T
    Bull Soc Pathol Exot; 2015 Oct; 108(4):290-8. PubMed ID: 26289547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings.
    Nardell E; Dharmadhikari A
    Int J Tuberc Lung Dis; 2010 Oct; 14(10):1233-43. PubMed ID: 20843413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.
    Sotgiu G; Pontali E; Migliori GB
    Eur Respir J; 2015 Jan; 45(1):25-9. PubMed ID: 25552734
    [No Abstract]   [Full Text] [Related]  

  • 18. Tuberculosis control goals unlikely to be met by 2005.
    Sharma DC
    Lancet; 2004 Apr; 363(9415):1122. PubMed ID: 15068013
    [No Abstract]   [Full Text] [Related]  

  • 19. Rational 'DOTS plus' for the control of MDR-TB.
    Espinal MA; Dye C; Raviglione M; Kochi A
    Int J Tuberc Lung Dis; 1999 Jul; 3(7):561-3. PubMed ID: 10423218
    [No Abstract]   [Full Text] [Related]  

  • 20. Programmes and principles in treatment of multidrug-resistant tuberculosis.
    Mukherjee JS; Rich ML; Socci AR; Joseph JK; Virú FA; Shin SS; Furin JJ; Becerra MC; Barry DJ; Kim JY; Bayona J; Farmer P; Smith Fawzi MC; Seung KJ
    Lancet; 2004 Feb; 363(9407):474-81. PubMed ID: 14962530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.